NVAX Novavax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX

Price (delayed)

$5.56

Market cap

$660.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.31

Enterprise value

$221.09M

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
Novavax's EPS has surged by 64% YoY and by 12% QoQ
Novavax's net income has soared by 58% YoY and by 6% from the previous quarter
Novavax's debt has decreased by 49% YoY but it has increased by 12% QoQ
Novavax's equity has decreased by 20% YoY but it has increased by 10% QoQ
The revenue has contracted by 43% YoY and by 34% from the previous quarter
NVAX's gross profit is down by 40% YoY and by 24% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com/
Peers: AGEN SRPT EBS BCRX

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
118.79M
Market cap
$660.47M
Enterprise value
$221.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Earnings
Revenue
$1.05B
EBIT
-$535.94M
EBITDA
-$498.29M
Free cash flow
-$726.79M
Per share
EPS
-$6.31
Free cash flow per share
-$7.03
Book value per share
-$7.19
Revenue per share
$10.15
TBVPS
$14.83
Balance sheet
Total assets
$1.66B
Total liabilities
$2.34B
Debt
$222.11M
Equity
-$678.35M
Working capital
-$461.83M
Liquidity
Debt to equity
-0.33
Current ratio
0.69
Quick ratio
0.53
Net debt/EBITDA
0.88
Margins
EBITDA margin
-47.5%
Gross margin
64.7%
Net margin
-52.3%
Operating margin
-54.7%
Efficiency
Return on assets
-30.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-284.2%
Return on sales
-51.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-2.97%
1 week
2.96%
1 month
-12.44%
1 year
-66.96%
YTD
-45.91%
QTD
-23.2%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.05B
Gross profit
$679.21M
Operating income
-$573.82M
Net income
-$548.92M
Gross margin
64.7%
Net margin
-52.3%
Novavax's net income has soared by 58% YoY and by 6% from the previous quarter
Novavax's operating income has soared by 53% YoY
The operating margin has dropped by 52% since the previous quarter but it has increased by 17% year-on-year
Novavax's net margin has decreased by 43% QoQ but it has increased by 27% YoY

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
0.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Novavax's EPS has surged by 64% YoY and by 12% QoQ
Novavax's equity has decreased by 20% YoY but it has increased by 10% QoQ
NVAX's P/S is 96% below its 5-year quarterly average of 14.2 but 12% above its last 4 quarters average of 0.5
The revenue has contracted by 43% YoY and by 34% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has decreased by 44% QoQ but it has increased by 26% YoY
NVAX's return on assets is up by 40% year-on-year

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 29% lower than its total liabilities
NVAX's quick ratio is down by 37% year-on-year and by 7% since the previous quarter
The current ratio has declined by 35% year-on-year and by 2.8% since the previous quarter
Novavax's debt is 133% higher than its equity
NVAX's debt to equity has surged by 57% year-on-year but it is down by 27% since the previous quarter
Novavax's debt has decreased by 49% YoY but it has increased by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.